NHS is not just playing with fire, it's lighting them—all part of the (hairbrained) plan
More joining of dots in the UKs quest to conquer the world with gene therapy
What is ‘The ATTC project?’
ATTC stands for “Advanced Therapy Treatment Centres”. Its website explains the mission:
“Our Mission
The ATTC project aims to develop robust systems for the routine delivery of ATMPs as a standard of care throughout the NHS in the United Kingdom.”
It then goes on to say:
“Over the last five years, new cell and gene therapies have been developed to treat some cancers and inherited diseases. These advanced therapies are different from existing treatments in two important ways: they are designed to restore normal function, sometimes offering cures where an unmet medical need exists and they require new ways of working by the NHS.”
The truth is very different
Some very disturbing facts seem to have been missed out. Nearly all the potential for gene therapies is wrapped up in rare blood cancers, where the treatment is known as CAR T.
The first to market was Novartis’ Kymriah, approved August 2017:
Price at launch was $475,000.
Hospitals have to fund additional heavy overheads to deliver the treatment.
They are autologous therapies, which mean they are specific to the patient.
Therefore, the manufacturing and cold chain logistics issues are immense.
The side effects are cytokine release syndrome (CRS) and neurological toxicities.
[Find out more about this whole area in my TrialSite News article Gene therapy—is it really a sound investment prospect?]
Similar price tags and issues are associated with other CAR-T programmes, and for cell and gene therapy in general.
Check out UKs Cell and Gene Therapy 2021 database of clinical trials, which shows the massive amount of activity in developing ATMPs, with very little getting to market. Some of the trials date back to 2013!
[as an aside, ask yourself how the vaccine companies did it in 9 months]
Back to the ATTC network programme
The ATTC website continues:
“The ATTC network programme is a world-first, UK system of Advanced Therapy Treatment Centres (ATTC) operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult (CGT Catapult) to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients. The centres include:
I invite you to click on the three links, and scroll down to view the plethora of organisations involved, public, private and not-for-profit. Puts me in mind of the camel designed by a committee—23 heads, 37 humps, 14 legs and an elephant’s trunk :)
Undeterred by untold numbers of fingers in the pie, this is the aim:
“As a goal of this three year project, the ATTCs are working together with industry partners and the public sector to develop the necessary processes, skilled staff and infrastructure at scale as more treatments move from clinical trial to marketed products.”
Now, I’m fighting against sarcasm at this point. These therapies are going to enter the bodies of living humans. The hospital pharmacy is going to be in charge of taking frozen ‘vaccines’ from the manufacturer and converting them into the final dose administered to the living human (MHRA has changed the regulations in January 2022 to allow that). Is that dangerous, or is that highly dangerous?
Yes, but we have this up our sleeves, we hear them cry:
Advanced Therapies NHS Readiness Toolkit…
…which includes this: Quality assurance and risk management.
That makes them experts then! (sorry, that sarcasm keeps taking over me)
Then we learn:
“The CGT Catapult is playing a central coordination role for the network and provide support to manufacturing, supply chain logistics, regulatory affairs, clinical trial capability, R&D support and upskilling via specialist training and development.”
So, ask yourself, is this a hairbrained undertaking? Is this part of an even more hairbrained plan?
The hairbrained plan
My take on it is here:
UK is testbed for mass vaccination with gene therapies, leading to global rollout…
…and here is the bones of the ‘plan’:
Oh boy, and here in the US, I always thought of the push for socialized medicine/Obamacare/Hillarycare would only require a Mind boggling tax structure policy to fleece the citizens. Little did I realize. This UK plan is frightening, not so much in what it may cost you (us) all monetarily, but what it will cost you (us) if you’re (we’re) not interested in participating. Once again, Hedley, thank you for your courageous shining of the light.
What could possibly go wrong, particularly when they're already ignoring the under-reported yellow card problems from the new mRNA vaccines? I clicked on the third link and had a wry smile at the old bakelite telephone behind the steering group leader.